Acutely administered antipsychotic drugs are highly selective for dopamine D2 over D3 receptors

被引:20
作者
McCormick, Patrick N. [1 ]
Wilson, Virginia S. [1 ]
Wilson, Alan A. [1 ,2 ]
Remington, Gary J. [1 ,2 ]
机构
[1] Ctr Addict & Mental Hlth, Toronto, ON M5T 1R8, Canada
[2] Univ Toronto, Dept Psychiat, Toronto, ON, Canada
关键词
Antipsychotic drugs; Dopamine D2 receptor; Dopamine D3 receptor; Selectivity; H-3]-(+)-PHNO; Rat; POSITRON-EMISSION-TOMOGRAPHY; HIGH-AFFINITY STATE; PHARMACOLOGICAL CHARACTERIZATION; SEROTONIN TRANSPORTER; D-3; RECEPTORS; PET; BINDING; VIVO; QUANTIFICATION; MICRODIALYSIS;
D O I
10.1016/j.phrs.2013.01.002
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
We showed previously, using [H-3]-(+)-4-propyl-9-hydroxynaphthoxazine ([H-3]-(+)-PHNO) autoradiography, that several antipsychotic drugs do not occupy dopamine D3 receptors at clinically-relevant doses in rat. This is an unexpected finding considering the near-equivalent in vitro affinity of these drugs for D2 and D3 receptors. The purpose of the current study was to address two possible methodological limitations of our previous report, namely that (1) [H-3]-(+)-PHNO may have been administered at non-tracer dose, potentially causing underestimate of D3 receptor occupancy, and (2) antipsychotic drugs were administered chronically, potentially causing increased D3 receptor expression not accounted for in the vehicle-treated control group. We found that decreasing [H-3]-(+)-PHNO dose from 5.6 nmol/kg (our previous dose) to 0.6 nmol/kg caused a >60% increase in [H-3]-(+)-PHNO binding to D3 receptors in cerebellar lobes 9 and 10, indicating that our previous study was indeed conducted under non-tracer dose conditions. However, neither reducing [H-3]-(+)-PHNO dose further to 0.3 nmol/kg (a tracer dose), nor administering antipsychotics acutely affected antipsychotic receptor occupancy. At clinically-relevant levels of D2 occupancy (57-82% inhibition of striatal binding), neither olanzapine nor haloperidol occupied D3 receptors, while clozapine occupied D3 receptors at levels similar to our previous report (33%). Risperidone moderately occupied D3 receptors (40%), but at a dose occupying >90% of D2 receptors and therefore of questionable clinical relevance. These findings demonstrate that the lack of antipsychotic occupancy of D3 receptors is not attributable to limitations of our previous study. These results suggest that D3 receptor blockade is not necessary for the therapeutic effects of the antipsychotic drugs examined. (C) 2013 Elsevier Ltd. All rights reserved.
引用
收藏
页码:66 / 71
页数:6
相关论文
共 50 条
  • [41] Mechanism of action of antipsychotic drugs:: From dopamine D2 receptor antagonism to glutamate NMDA facilitation
    Laruelle, M
    Frankle, WG
    Narendran, R
    Kegeles, LS
    Abi-Dargham, A
    CLINICAL THERAPEUTICS, 2005, 27 : S16 - S24
  • [42] The Impact of Selective Dopamine D2, D3 and D4 Ligands on the Rat Gambling Task
    Di Ciano, Patricia
    Pushparaj, Abhiram
    Kim, Aaron
    Hatch, Jessica
    Masood, Talal
    Ramzi, Abby
    Khaled, Maram A. T. M.
    Boileau, Isabelle
    Winstanley, Catherine A.
    Le Foll, Bernard
    PLOS ONE, 2015, 10 (09):
  • [43] Affinity and selectivity of [11C]-(+)-PHNO for the D3 and D2 receptors in the rhesus monkey brain in vivo
    Gallezot, Jean-Dominique
    Beaver, John D.
    Gunn, Roger N.
    Nabulsi, Nabeel
    Weinzimmer, David
    Singhal, Tarun
    Slifstein, Mark
    Fowles, Krista
    Ding, Yu-Shin
    Huang, Yiyun
    Laruelle, Marc
    Carson, Richard E.
    Rabiner, Eugenii A.
    SYNAPSE, 2012, 66 (06) : 489 - 500
  • [44] Differential induction of adenylyl cyclase supersensitivity by antiparkinson drugs acting as agonists at dopamine D1/D2/D3 receptors vs D2/D3 receptors only: Parallel observations from co-transfected human and native cerebral receptors
    Aloisi, Gabriella
    Silvano, Elena
    Rossi, Mario
    Millan, Mark J.
    Maggio, Roberto
    NEUROPHARMACOLOGY, 2011, 60 (2-3) : 439 - 445
  • [45] Respective roles of dopamine D2 and D3 receptors in food-seeking behaviour in rats
    Duarte, C
    Biala, G
    Le Bihan, C
    Hamon, M
    Thiébot, MH
    PSYCHOPHARMACOLOGY, 2003, 166 (01) : 19 - 32
  • [46] Homology Modeling of Dopamine D2 and D3 Receptors: Molecular Dynamics Refinement and Docking Evaluation
    Platania, Chiara Bianca Maria
    Salomone, Salvatore
    Leggio, Gian Marco
    Drago, Filippo
    Bucolo, Claudio
    PLOS ONE, 2012, 7 (09):
  • [47] Risk-Taking Behavior: Dopamine D2/D3 Receptors, Feedback, and Frontolimbic Activity
    Kohno, Milky
    Ghahremani, Dara G.
    Morales, Angelica M.
    Robertson, Chelsea L.
    Ishibashi, Kenji
    Morgan, Andrew T.
    Mandelkern, Mark A.
    London, Edythe D.
    CEREBRAL CORTEX, 2015, 25 (01) : 236 - 245
  • [48] Dopamine D2/D3 imbalance during migraine attack and allodynia in vivo
    DaSilva, Alexandre F.
    Nascimento, Thiago D.
    Jassar, Hassan
    Heffernan, Joseph
    Toback, Rebecca L.
    Lucas, Sarah
    DosSantos, Marcos F.
    Bellile, Emily L.
    Boonstra, Philip S.
    Taylor, Jeremy M. G.
    Casey, Kenneth L.
    Koeppe, Robert A.
    Smith, Yolanda R.
    Zubieta, Jon-Kar
    NEUROLOGY, 2017, 88 (17) : 1634 - 1641
  • [49] Selective Overexpression of Dopamine D3 Receptors in the Striatum Disrupts Motivation but not Cognition
    Simpson, Eleanor H.
    Winiger, Vanessa
    Biezonski, Dominik K.
    Haq, Iram
    Kandel, Eric R.
    Kellendonk, Christoph
    BIOLOGICAL PSYCHIATRY, 2014, 76 (10) : 823 - 831
  • [50] New Dopamine D2 Receptor Agonist, [3H]MCL-536, for Detecting Dopamine D2high Receptors in Vivo
    Subburaju, Sivan
    Sromek, Anna W.
    Seeman, Philip
    Neumeyer, John L.
    ACS CHEMICAL NEUROSCIENCE, 2018, 9 (06): : 1283 - 1289